University Medical Center Hamburg-EppendorfGermany
Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .
Swiss Federal Institute of Technology in LausanneSwitzerland
Sandro Carrara is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Bio/CMOS Interfaces (BCI) laboratory. He is affiliated with the School of Engineering (STI), the Institute of Electrical Engineering (SCI-STI-SC), and the Integrated Systems Laboratory (LSI). His academic leadership spans teaching, doctoral supervision, and editorial roles in major journals including IEEE Sensors Journal and BioNanoScience. Education: Diploma in Electronics, National Technical Institute of Albenga, Italy Master in Physics, University of Genoa, Italy PhD in Biochemistry and Biophysics, University of Padua, Italy His research focuses on the integration of biological systems with CMOS technology, particularly in the development of nanoscale biosensors for health monitoring. Key areas include memristive biosensors, wearable and implantable sensors, electrochemical detection, and therapeutic drug monitoring. His work bridges electronics, nanotechnology, and biomedicine to enable point-of-care diagnostics and personalized medicine. His recent publications (2023–2025) show a strong trend toward sustainable printed electronics, machine learning for biosensing, in-memory computing for cancer diagnostics, and remote health monitoring. These works appear in high-impact journals such as IEEE Sensors Journal , Nanoscale , and Biosensors and Bioelectronics: X . Scientific Awards: IEEE Fellow (2015) IEEE Sensors Council Technical Achievement Award (2016) Distinguished Lecturer, IEEE Sensors Council (2017) Best Paper Award, IEEE MeMeA Symposium (2020) Multiple Gold and Bronze Leaf Prizes at PRIME and IEEE conferences Best Poster Awards at EMBEC and Nano-Tera meetings He actively advises PhD students and leads research projects involving CMOS-based biosensors, wireless implants, and smart sensor systems. His lab collaborates widely across disciplines and institutions, focusing on real-world applications in oncology, neurology, and environmental health. He has also contributed to the development of battery-free wearable devices, optical power transfer systems, and IoT-enabled telemedicine platforms. Laboratories and Teams: Bio/CMOS Interfaces (BCI) Laboratory, EPFL Integrated Systems Laboratory (LSI), EPFL Collaborations with IEEE Sensors Council and Circuits and Systems Society Editorial leadership in IEEE Sensors Journal and BioNanoScience
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
Christopher Kanan is a tenured Associate Professor of Computer Science at the University of Rochester, leading the AI Initiative within the Hajim School of Engineering & Applied Sciences. He holds secondary appointments in Brain and Cognitive Sciences, the Goergen Institute for Data Science and AI (GIDS-AI), and the Center for Visual Science. His research focuses on deep learning systems for artificial general intelligence (AGI), including continual learning, medical computer vision, and visual question answering. Previously, he was an Associate Professor at RIT’s Carlson Center for Imaging Science and a leader at Paige.AI, contributing to the FDA-cleared Paige Prostate system. Kanan earned his PhD from UC San Diego, completed postdoctoral work at Caltech, and worked at NASA JPL. Education: PhD in Computer Science, UC San Diego MS in Computer Science, University of Southern California Bachelor’s in Philosophy and Computer Science, Oklahoma State University Research Interests: Kanan’s work spans foundational AI capabilities like continual learning, medical imaging (pathology and radiology), multi-modal reasoning, and cognitive science-inspired models. His lab develops bias-robust AI systems and applies deep learning to healthcare and fusion research. Articles Trends: His recent work emphasizes out-of-distribution generalization, foundation models in pathology, and stability in continual learning. Key themes include AI applications in healthcare, model robustness, and neuroscience-inspired algorithms. Awards: NSF CAREER Award Senior Member, AAAI and IEEE DoE and NSF grants totaling $5M+ DARPA/ARL awards Advising & Grants: Mentored over 10 PhD students, including Robik Shrestha and Usman Mahmood. Secured grants for AI in nuclear fusion and medical imaging. Led RIT’s Center for Human-aware AI (CHAI) as Associate Director. Labs & Teams: Heads the University of Rochester AI Initiative, collaborates with Paige.AI, and leads teams advancing AI in pathology and robotics. His lab’s KLab (klab.cis.rit.edu) focuses on vision and learning systems.
David Erickson is the SC Thomas Sze Director and Sibley College Professor at Cornell University's Sibley School of Mechanical and Aerospace Engineering. He also holds a joint professorship in the Division of Nutritional Sciences. His research focuses on global health technologies, medical diagnostics, microfluidics, photonics, nanotechnology, and energy systems. He previously served as Associate Dean of Engineering for Research and Graduate Programs. Erickson leads the NIH-funded PORTENT Center for Point-of-Care Technologies in Global Health and has co-founded companies like Dimensional Energy and VitaScan to commercialize diagnostic and energy technologies. Education: B.Sc., Mechanical Engineering, University of Alberta (1999) M.A.Sc., Mechanical Engineering, University of Toronto (2001) Ph.D., Mechanical Engineering, University of Toronto (2004) Postdoctoral Scholar, Electrical Engineering, California Institute of Technology (2005) Research Interests: Erickson’s work spans global health diagnostics , nanobio applications , and clean energy innovation . He develops portable medical devices for low-resource settings, including smartphone-integrated diagnostic tools for malaria, iron deficiency, and cancer. His lab also pioneers photothermal reactors for CO2 conversion into sustainable fuels. Key areas include: Point-of-care testing for infectious diseases and nutritional deficiencies Nanofluidic and optofluidic technologies for biomolecular analysis Solar-driven energy systems for carbon-neutral fuels Awards: Presidential Early Career Award for Scientists and Engineers (2011) Fellowships from the Optical Society, ASME, and Canadian Academy of Engineering Carbon X-Prize Finalist (2019) for Dimensional Energy’s CO2-to-fuel technology Grants & Industry Collaboration: Erickson’s research is funded by NIH, NSF, ARPA-E, DOE, and USAID. His lab’s innovations have spun off start-ups addressing global health and energy challenges. Notable projects include: - Portable cancer diagnostics in sub-Saharan Africa using mobile phone-based systems - Solar-powered CO2 conversion reactors tested in Wyoming and Arizona Labs & Teams: The Erickson Lab collaborates with the Cornell Atkinson Center for Sustainability and the McGovern Center for Entrepreneurship. Key initiatives include the PORTENT Center and the Dimensional Energy CO2-to-fuel project.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Tim Q. Duong, Ph.D., is a Professor at Albert Einstein College of Medicine, affiliated with the Departments of Radiology, Biochemistry, Ophthalmology & Visual Sciences, and Neuroscience. His research focuses on medical imaging, MRI, image analysis, machine learning, and predictive modeling for studying diseases like COVID-19 , neurodegeneration (Alzheimer's, multiple sclerosis), brain injuries , and breast cancer . Develops AI-driven MRI techniques for early disease detection Investigates neuroplasticity in glaucoma and diabetic retinopathy Leads grants from NIH and National Eye Institute Research Trends : Recent publications emphasize AI integration in medical imaging, long-term effects of SARS-CoV-2, and advanced MRI applications for ocular and neurological disorders. Grants include multiple R01 awards for diabetic retinopathy and glaucoma studies. Training Opportunities : Actively recruits postdocs, research coordinators, and faculty. Offers research positions for graduate, medical, and high school students, including Regeneron Scholar programs. Labs & Teams : Leads the Duong Lab at Montefiore Medical Center, focusing on translational research for clinical imaging solutions.
Mayo Clinic College of Medicine and ScienceUnited States
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Ruth Etzioni is an Affiliate Professor in the Biostatistics Program and Public Health Sciences Division at the Fred Hutchinson Cancer Center. She leads the Etzioni Lab, focusing on cancer screening, early detection, and overdiagnosis analysis. Her work integrates statistical modeling, epidemiology, and clinical research to address critical questions in prostate and breast cancer control. Dr. Etzioni holds the Rosalie & Harold Rea Brown Endowed Chair and has received a $7.4M NIH Outstanding Investigator Award. Education: PhD in Statistics (Carnegie Mellon University, 1990), MS in Statistics (Carnegie Mellon, 1987), BS in Mathematics (University of Cape Town, South Africa). Research interests emphasize biomarkers, clinical trials, and epidemiological methods. She leads the Biostatistics Core for the Pacific Northwest Prostate Cancer SPORE and participates in the Cancer Intervention and Surveillance Modeling Network (CISNET). Her lab develops models to evaluate screening policies, quantify overdiagnosis, and inform healthcare disparities reduction strategies. Key achievements include groundbreaking work on prostate cancer screening's harm-benefit tradeoffs and contributions to multi-cancer early detection (MCED) frameworks. Recent studies address racial disparities in prostate cancer outcomes, metastasis trends, and the clinical utility of novel diagnostics like PSMA PET imaging. Awards include the Brown Endowed Chair (2020), NCI OIA Award (2023), and recognition for advancing cancer data science. Her lab collaborates with institutions globally and mentors students in biostatistics and translational data science.
Prof. Abbas Samani is a Professor at the Department of Electrical and Computer Engineering and holds a joint appointment in the Department of Medical Biophysics at Western University . He is a core faculty member of the Biomedical Engineering Graduate Program and an Associate Scientist at Imaging Research Laboratories of Robarts Research Institute . His academic journey includes a Ph.D. from the University of Waterloo, an M.Sc. from the University of Tehran, and a B.Sc. from Amirkabir University of Technology. His research focuses on biological tissue computational modeling and its applications in medical imaging, intervention, and image analysis . He develops computer/image-assisted tools for minimally invasive disease diagnosis and therapy , targeting heart disease, cancer, and lung disease . Key projects include myocardium biomechanical modeling , handheld medical devices for breast cancer screening , and lung disease diagnostics via CT image segmentation . His recent publications emphasize ultrasound elastography , finite element modeling , and inverse problems in biomechanics , primarily in journals like IEEE Transactions on Computational Imaging and Translational Oncology . His work spans both computational modeling and medical device development . Selected Graduate Supervision : Ph.D. Candidates : Seyed Hassan Haddad, Elham Karami, Seyed Mohammad Hesabgar Graduated Ph.D. Students : Ali Sadeghi Naini, Seyed Reza Mousavi M.Sc. Students : Cristian Linte, Patrick Courtis, Joseph O'Hagan, Hatef Mehrabian, Hirad Karimi, Hosein Amooshahi, Seyed Mohammad Hesabgar, Nastaran Ghadarghadr, Shadi Shavakh, Ehsan Salamati, Ehsan Omidi Teaching Contributions : Graduate: BME9519B/CAMI9519B/ECE9202B/ECE9022B - Advanced Image Processing and Analysis , MBP9530A - Human Biomechanics and Biomedical Applications Undergraduate: ECE4438B - Advanced Image Processing and Analysis , ES1050 - Introductory Engineering Design and Innovation Studio , MBP3330F - Human Biomechanics and Biomedical Applications Research Affiliations : Robarts Research Institute - Associate Scientist at Imaging Research Laboratories Western University - Core Faculty, Biomedical Engineering Graduate Program
Lawrence Staib is Professor of Radiology and Biomedical Imaging, Biomedical Engineering, and Electrical Engineering at Yale University. He serves as Director of Undergraduate Studies in Biomedical Engineering and is a member of Yale's Bioimaging Sciences division, Image Processing & Analysis Group, Yale Biomedical Imaging Institute, and Yale-BI Biomedical Data Science Fellowship program. Dr. Staib earned his A.B. in Physics from Cornell University (1982), followed by a Ph.D. in Engineering and Applied Science from Yale University (1990), and completed a postdoctoral fellowship at Yale School of Medicine (1991). His research focuses on developing advanced medical image analysis methods using machine learning and model-based approaches. Key research areas include neuroimaging applications for autism spectrum disorder classification, cardiac imaging analysis for strain and motion assessment, prostate cancer diagnosis and risk mapping, and innovative techniques for medical image segmentation with limited labeled data. Dr. Staib's work emphasizes uncertainty estimation in deep learning models, multi-modal image registration, and domain adaptation techniques to improve clinical decision support systems. His recent publications demonstrate a strong trend toward developing interpretable AI models for clinical applications, with particular emphasis on fMRI analysis for neurological conditions, cardiac motion analysis, and prostate cancer diagnosis. His work frequently addresses the challenge of limited labeled data in medical imaging through innovative self-supervised, semi-supervised, and few-shot learning approaches. Fellow of the American Institute for Medical and Biological Engineering (AIMBE) (2015) Distinguished Investigator Award from the Academy for Radiology & Biomedical Imaging Research (2017) MICCAI Fellow (2022) Medical Image Analysis Second Best MICCAI Paper Award (2005) ASNR Cum Laude Scientific Exhibit Award (2003) Dr. Staib serves on the editorial board of Medical Image Analysis and as Associate Editor of IEEE Transactions on Biomedical Engineering. His research is supported by NIH grants including the Autism Center of Excellence program. He leads the Image Processing & Analysis Group within Yale's Bioimaging Sciences division, collaborating extensively with James Duncan, John Onofrey, Xenophon Papademetris, and other Yale researchers on applications spanning neuroimaging, cardiology, and oncology. Current projects focus on developing robust AI models for clinical decision support with emphasis on uncertainty quantification and interpretability.
Hong Han is an Assistant Professor in the Department of Biochemistry & Biomedical Sciences within McMaster University's Faculty of Health Sciences and a member of the Centre for Discovery in Cancer Research (CDCR). She holds a Canada Research Chair and leads the Han Lab, which focuses on cancer biology, RNA regulation, and innovative high-throughput technologies for therapeutic discovery. Dr. Han earned her Ph.D. from the University of Toronto (2010-2016) and has established herself as a leading researcher in glioblastoma and alternative splicing regulation. Her interdisciplinary research integrates cancer biology, RNA science, and multilayer gene regulation to uncover mechanisms underlying cancer progression and treatment resistance. Her laboratory pioneers integrated technological platforms for large-scale genetic/drug screening and ultra-high-throughput single-cell profiling. The research focuses on three main areas: alternative splicing regulation in cancer (particularly glioblastoma and prostate cancer), multilayer mechanisms of glioblastoma heterogeneity and microenvironment evolution, and multiplexed screening approaches for therapeutic discovery in treatment-resistant cancers. Analysis of Dr. Han's recent publications reveals a strong emphasis on single-cell technologies to characterize glioblastoma heterogeneity, minimal residual disease states, and tumor-immune interactions. Her work increasingly bridges basic RNA biology with translational applications, particularly in developing novel therapeutic strategies targeting splicing networks and immune evasion mechanisms. Canada Research Chair Dr. Han teaches Advanced Techniques in the Biomedical Sciences (BIOCHEM 734). Her research program is supported by multiple funding sources, as evidenced by her extensive publication record in high-impact journals including Nature, Cell, Molecular Cell, and Nature Communications. She employs a comprehensive approach combining in vitro, in vivo, and patient cohort studies with cutting-edge genomic technologies. The Han Lab has developed innovative multiplexed screening platforms that enable simultaneous interrogation of thousands of conditions, ranging from CAR-T cells to small molecule therapeutics. This approach accelerates the discovery of novel cancer targets and therapeutic strategies for treatment-resistant cancers.
University of California, San FranciscoUnited States
Iona Cheng is a Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), where she conducts groundbreaking research in cancer epidemiology. She serves as co-Investigator of the SEER Greater Bay Area Cancer Registry and is Principal Investigator of multiple NIH- and foundation-funded projects examining genetics, lifestyle factors, and neighborhood characteristics in relation to cancer risk. Dr. Cheng has developed an extensive research program focused on racial/ethnic differences in cancer risk and leads population-based cancer surveillance studies that document variations in cancer incidence and mortality patterns across diverse racial and ethnic groups. University of California, Davis, BS, 1990–1994, Physiology Yale University, MPH, 1999–2001, Chronic Disease Epidemiology University of Southern California, PhD, 2001–2005, Epidemiology University of California, San Francisco, Postdoc, 2006–2008, Genetic and Molecular Epidemiology Dr. Cheng's research spans multiple disciplines within cancer epidemiology, with particular emphasis on understanding how environmental exposures, genetic factors, and social determinants interact to influence cancer risk and outcomes across different racial and ethnic populations. Her work frequently examines the impact of air pollution, endocrine-disrupting chemicals, and neighborhood characteristics on cancer development and survival. She has made significant contributions to understanding cancer disparities among Asian American, Native Hawaiian, and Pacific Islander populations, bringing attention to the unique cancer risks and outcomes within these understudied groups. Her research often leverages the Multiethnic Cohort Study, one of the largest prospective studies of cancer incidence and mortality across diverse racial/ethnic populations. Analysis of Dr. Cheng's recent publications reveals a consistent focus on environmental and social determinants of cancer risk across multiple organ sites. Her work demonstrates a sophisticated integration of epidemiological methods with environmental exposure assessment, genetic analysis, and health disparities research. Many of her studies examine the intersection of environmental exposures and racial/ethnic disparities in cancer outcomes, particularly regarding breast cancer, lung cancer, and other malignancies. She has published extensively on the impact of air pollution on cancer risk and survival, as well as the effects of endocrine-disrupting chemicals like bisphenol A, parabens, and phthalates. American Association for Cancer Research Scholar-in-Training Award (2007) National Institutes of Health Loan Repayment Award (2007) National Institutes of Health Loan Repayment Renewal Award (2009) American Association for Cancer Research Faculty Scholar Award (2011) National Institutes of Health Loan Repayment Renewal Award (2011) National Institutes of Health Loan Repayment Renewal Award (2013) American Journal of Epidemiology/Society of Epidemiology Research Top 10 manuscripts (2014) Cancer Prevention Institute of California Mentoring Award (2015) American Society of Human Genetics Top poster As Principal Investigator of multiple NIH-funded projects, Dr. Cheng oversees substantial research grants focused on cancer epidemiology and health disparities. Her work often involves large interdisciplinary collaborations with researchers across multiple institutions, including the Multiethnic Cohort Study which follows over 200,000 participants from diverse racial/ethnic backgrounds. She has demonstrated leadership in mentoring junior researchers, particularly those from underrepresented backgrounds in science, as evidenced by her Cancer Prevention Institute of California Mentoring Award. Her research program integrates data from cancer registries, electronic health records, and geospatial information to provide comprehensive insights into cancer patterns and risk factors. Dr. Cheng's research is closely connected to the UCSF Helen Diller Family Comprehensive Cancer Center and leverages collaborations with Lawrence Berkeley National Laboratory, which provides advanced technological resources for cancer research. Her work benefits from access to extensive cohort data, sophisticated exposure assessment methods, and interdisciplinary expertise in genetics, environmental science, and computational biology available through these institutional partnerships. She frequently collaborates with researchers studying the genetic and environmental determinants of cancer across multiple organ systems, contributing to a more comprehensive understanding of cancer etiology and prevention strategies.
Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).
